EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, OncoCyte's enterprise value is $26.52 Mil.
OncoCyte's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1.50 Mil. Therefore, OncoCyte's EV-to-Revenue for today is 17.64.
The historical rank and industry rank for OncoCyte's EV-to-Revenue or its related term are showing as below:
OCX'
s EV-to-Revenue Range Over the Past 10 Years
Min: -222.68 Med: 47.19 Max: 12297.08
Current: 17.64
During the past 11 years, the highest EV-to-Revenue of OncoCyte was 12297.08. The lowest was -222.68. And the median was 47.19.
OCX's EV-to-Revenue is ranked worse than 88.55% of 227
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.02
vs OCX: 17.64
As of today (2024-04-29), OncoCyte's stock price is $2.525.
OncoCyte's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.20. Therefore, OncoCyte's PS Ratio for today is 12.82.
OncoCyte EV-to-Revenue Historical Data
The historical data trend for OncoCyte's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of OncoCyte's EV-to-Revenue
For the Diagnostics & Research subindustry, OncoCyte's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoCyte's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where OncoCyte's EV-to-Revenue falls into.
OncoCyte's current Enterprise Value is $26.52 Mil.
OncoCyte's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoCyte's share price for today is $2.525.
OncoCyte's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoCyte EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of OncoCyte's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCX has been successfully added to your 